Huawei’s pharmaceutical unit targets AI, not drug development
TMTPost reports that Huawei established a pharmaceutical unit in December 2025, with president Fan Jie positioning the team as an AI enabler for the pharmaceutical industry rather than a developer of medicines or drug pipelines. The article also examines how OpenAI, Anthropic, ByteDance, NVIDIA, Meta and other technology companies have expanded into AI-assisted drug discovery, while noting that AI has yet to demonstrate clear advantages in Phase II and III clinical trials.
Huawei’s new unit marks a material expansion into healthcare AI, but the broader corporate actions and clinical comparisons are based largely on commentary and claims reported by a single outlet.
(本文作者为 商隐社,钛媒体经授权发布)
文 | 商隐社
最近读了一本关于制药的书,其中的一句话让我很震惊:
尽管大型制药公司付出了巨大努力,但21世纪猎药的主要技术跟5000年前并没什么两样——煞费苦心地从数量庞大的混合物中抽样做实验,希望能有一种是有效的。
当然,作者写下这些话的时候AI制药还没像今天这样火热,我不禁想,AI制药能改变这种状况吗?
然后这几年一些科技巨头,比如OpenAI、Anthropic、字节、英伟达、Meta、华为等都不同程度地踏入了制药行业,他们在其中扮演什么角色?
#Huawei#Huawei Pharmaceutical Corps#OpenAI#GPT-Rosalind#Anthropic#ByteDance#Anew Labs#NVIDIA#Meta#Isomorphic Labs#Coefficient Bio#Claude Science